Back to search results

Anthocyanin-Rich Table Grape Powder for Preventing Post-Operative Atrial Fibrillation

This study is exploring whether consuming Freeze-Dried California Table Grape powder can help prevent Post-operative Atrial Fibrillation (POAF), a common heart rhythm problem after heart surgery. POAF is thought to be linked to inflammation, and this study aims to see if the grape powder, which has anti-inflammatory properties, can reduce its occurrence. You would consume two servings of either the grape powder or a placebo (an inactive substance) daily for three days before your heart surgery. Researchers will then track POAF-related events during your hospital stay and for 30 days after surgery. They will also look at how the treatment affects certain markers in your heart tissue and conditions like NIDDM (Type 2 Diabetes) and Angiotensin II (a hormone that affects blood pressure). This study is currently on hold for new participants while the research plan is being updated.

Study design
This is an interventional study planning to enroll 70 participants. It compares Freeze-Dried California Table Grape powder to a placebo.
What's involved
You would consume two servings of either the grape powder or a placebo daily for three days before your cardiac surgery.
Compensation
Not stated in the trial record.
Follow-up
Researchers will follow up on POAF-related events during your initial hospital stay and for 30 days after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05991700

Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation

Recruiting
PHASE1Ages 18–79InterventionalPrevention
University of Michigan
~70 participants
Updated 2026-04-27 on ClinicalTrials.gov
What's tested:Freeze-Dried California Table GrapePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
POAF-related events during initial hospital stay and within 30 days after surgery
Measured over 30 days
+1 more outcome measured

Conditions

Post-operative Atrial Fibrillation (POAF)

Explore related trials

Atrial Fibrillation

NCT05991700

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Michigan - Michigan Medicine

    Ann Arbor, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

China Green, BS
[email protected]
734-936-7731
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males and female patients (age 50-79) at the Mitral Valve Clinic/CVC undergoing elective cardiac surgery for mitral valve repair without the Cox MAZE procedure (MVR patients also undergoing CABG and/or tricuspid valve repair are also eligible)
In sinus rhythm (no pre-operative atrial fibrillation)

Exclusion

Age ≥ 80 years
Diagnosed pre-operative chronic or paroxysmal AF
Prior ablation procedure for AF
Previous cardiac surgery
Implanted pacemaker
Active smoker
Comorbidities such as congenital or cardiac re-operation
Use of antiarrhythmic agents
Active inflammatory or infectious disease or malignancy
Diagnosed autoimmune disease
Corticosteroid or other immunomodulatory or immunosuppressive medication
Risk factors for POAF including low ejection fraction (EF) (EF\<50%), left atrial (LA) dilation (LA\>5.0 cm), and high degree of mitral regurgitation (grade 3-4).

What this trial measures

  • POAF-related events during initial hospital stay and within 30 days after surgery30 days
  • Atrial transcripts related to NFκB activation; Impact on NIDDM, Angiotensin II30 days